

Global Pneumococcal Vaccine Market Set for Robust Expansion, Projected to Reach \$11.36 Billion by 2028

Pneumococcal Vaccine Global Market Report 2024 – Market Size, Trends, And Forecast 2024-2033

LONDON, GREATER LONDON, UK, July 9, 2024 /EINPresswire.com/ -- The [global pneumococcal vaccine market](#) has witnessed significant growth, expanding from \$8.47 billion in 2023 to \$9.04 billion in 2024, at a compound annual growth rate (CAGR) of 6.7%. Despite challenges, the market is expected to reach \$11.36 billion by 2028, driven by evolving pneumococcal strains, continued research and development, and expanded vaccine access.



The Business
Research Company

Pneumococcal Vaccine Global Market Report 2024 – Market Size, Trends, And Forecast 2024-2033



You Can Now Pre Order
Your Report To Get A Swift
Deliver With All Your Needs”
*The Business research
company*

Increasing Prevalence of Pneumococcal Contamination Drives Market Growth

The rising prevalence of pneumococcal contamination is a major factor contributing to the growth of the pneumococcal vaccine market. Pneumococcal contamination, caused by *Streptococcus pneumoniae*, leads to infections such as pneumonia, bloodstream infections, ear infections, and sinus infections. The

pneumococcal vaccine stimulates the production of antibodies to combat these infections, offering protection to children, the elderly, and individuals with weakened immune systems. For instance, according to the CDC, pneumococcal pneumonia results in approximately 150,000 hospitalizations annually in the United States. Therefore, the increasing prevalence of pneumococcal contamination is driving market growth.

Explore comprehensive insights into the global pneumococcal vaccine market with a detailed sample report:

https://www.thebusinessresearchcompany.com/sample_request?id=11950&type=smp

Major Players and Market Trends

Key players in the pneumococcal vaccine market include Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Novartis International AG, Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, and more. These companies are focusing on developing conjugate vaccines, which offer enhanced protection by targeting multiple serotypes. For instance, in April 2023, Pfizer launched PREVNAR 20, a conjugate vaccine designed to protect against 20 pneumococcal serotypes.

Segments:

- Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products
- Route of Administration: Intravenous, Intramuscular, Subcutaneous
- Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels
- End User: Pediatrics, Adults

Geographical Insights: North America Leading the Market

North America was the largest region in the pneumococcal vaccine market in 2023, while Asia-Pacific is expected to be the fastest-growing region in the forecast period. The comprehensive report provides detailed insights into regional dynamics, market trends, and growth opportunities.

Order your report now for swift delivery

<https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report>

[Pneumococcal Vaccine Global Market Report 2024](#) from TBRC covers the following information:

- Market size data for the forecast period: Historical and Future
- Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
- Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.

The Pneumococcal Vaccine Global Market Report 2024 by The Business Research Company is the most comprehensive report that provides insights on pneumococcal vaccine market size, pneumococcal vaccine market drivers and trends, pneumococcal vaccine market major players, competitors' revenues, market positioning, and market growth across geographies. The pneumococcal vaccine market report helps you gain in-depth insights on opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company:

Veterinary Vaccines Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/veterinary-vaccines-global-market-report>

Companion Animal Veterinary Vaccines Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/companion-animal-veterinary-vaccines-global-market-report>

Cancer Vaccines Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report>

About [The Business Research Company?](#)

The Business Research Company has published over 27 industries, spanning over 8000+ markets and 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database

The Global Market Model, The Business Research Company's flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/726141413>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.